Table 4.

Loxapine, Metabolite Levels, and Changes in Outcomes

						Percent change from baseline to week 12
Subject	Final loxapine dose (mg/day)	Loxapine (ng/mL)	7-OH lox (ng/ml)	8-Hydroxyloxapine (ng/mL)	Amoxapine (ng/mL)	CGI-S	ABC-I	ABC-II	ABC-III	ABC-IV
1	7.5	1.8	0.3	1.2	0.6	−33%	28%	−16%	−6%	−19%
2	7.5	1.7	0.6	1.7	0.8	−20%	−25%	−6%	−45%	0%
3	15	1.9	0.7	4.3	0.2	−50%	−86%	−65%	−100%	−86%
4 (dropout)	2.5
5	5	3.4	0.9	2.1	0.7	−33%	0%	0%	0%	0%
6	10	3.9	1.7	7.9	1	−17%	−31%	−29%	8%	−29%
7	5	0.9	1.2	3.8	0.2	−20%	−50%	−39%	−54%	−27%
8	15	3.2	1.2	3.8	1	0%	−21%	−58%	−27%	0%
9	7.5	3.3	0	2	0.5	−20%	−40%	−48%	−39%	−77%
10	10	1.2	0.3	2.2	0.3	−17%	−7%	−20%	0%	0%
11	10	0.9	0.5	1.6	0.6	−33%	−68%	−64%	−57%	−74%
12	5	3.6	0.3	2	1.6	−33%	−9%	0%	−13%	−3%
13	10	5.1	0.6	6.6	0.8	−33%	−18%	−86%	−100%	−40%
14 (dropout)	5
15	10	1.9	0.7	4.6	0.2	−43%	−22%	−20%	−25%	−28%
16	10	2	1.3	3.3	0.7	−33%	−50%	−38%	−47%	−25%
Mean:		2.5	0.7	3.4	0.7

CGI-S, Clinical Global Impressions-Severity; ABC, Aberrant Behavior Checklist.